A Clinical Study Comparing Restylane® Silk and Belotero Balance® for the Treatment of Superficial, Vertical Perioral Lines

This will be a single-center, randomized, evaluator-blinded, split-face clinical study design. Fifty patients will receive one treatment session consisting of Restylane® Silk (right side of the face) and Belotero Balance® (left side), or vice versa (1:1 dose conversion ratio) injections to the superficial, vertical perioral lines. Injections will be performed at the baseline visit. To ensure subject and investigator blinding, syringes will be prepared and labeled "1" and "2" immediately before subject attendance for injection by the sub-investigator. The same injection sites and techniques will be used on both sides of the face. Then, patients will follow-up on post-treatment day 7, 14, 30, 60, 90, 120, 150, 180.

Study Overview

• Status: Unknown
• Conditions: Perioral Rhytids
• Intervention / Treatment: Drug: Restalyne Silk; Drug: Belotero Balance

• Study Type: Interventional
• Enrollment (Anticipated): 50
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94115
      • Recruiting
      • The Maas Clinic
      • Contact: Rachel Bass, B.S.; Phone Number: 415-567-8275; Email: research@maasclinic.com
      • Contact: Kyle Jennings, B.S; Phone Number: 415-567-7000; Email: research2@maasclinic.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients exhibiting moderate [2] to severe [3] superficial, vertical perioral lines on the 5-point Merz® validated scale for assessment of superficial perioral lines
• Females and males in good general health over the age of 18 years old

Must be willing to give and sign a HIPAA form, informed consent form and a photographic release form

• Patient is planning to undergo Restylane® Silk and Belotero Balance® injections
• For female patient of childbearing potential, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the patient become sexually active]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation
• Negative urine pregnancy test results at the time of study entry (if applicable)
• Must be willing to comply with study regimen and complete the entire course of the study.

Exclusion Criteria:

• A patient with any uncontrolled systemic disease. A potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study

A patient with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.

• A patient with a known hypersensitivity to any of the components of the study medications
• A patient who is actively smoking or plans to smoke at any time of the duration of this study
• A patient with an active skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis, herpes labialis)
• A patient planning any other cosmetic procedure to their facial area during the study period, other than the treatments that will be performed by the investigator
• A patient using any topical (prescription or over the counter) medicated creams, lotions, gels, balms, powders, etc. on the treatment areas during the study period
• A patient receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or D (includes derivatives thereof) on the perioral areas within 7 days prior to or during the study period, other than the study products
• A patient receiving any investigational drug and/or has had a microdermabrasion (light or medium skin peel) treatment on their perioral areas within 30 days prior to or during the study period
• A patient using any topical tretinoin product or derivative on their perioral areas within 12 weeks prior to or during the study period
• A patient receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio frequency treatment and/or has had a dermabrasion (deep skin peel) or ablative laser treatments on their perioral areas must have discontinued the drug/treatment and/or had the procedure at least 6 months prior to entering the study
• A patient that has previously been treated with botulinum toxin in the perioral areas within the past six months
• A patient that has previously been treated with dermal filler in the perioral areas within the past year
• A patient that with a history of allergic reaction to a dermal filler or lidocaine
• A patient that with a history of a permanent filler to the perioral areas
• A female patient who is pregnant, nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, intrauterine device, abstinence, or spermicides and condoms used in combination)]
• Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: Restylane Right, Belotero Left; Patients will receive one treatment with Restylane® Silk (right side of the face) and one treatment of Belotero Balance® (left side)	Drug: Restalyne Silk; Drug: Belotero Balance
OTHER: Restylane Left, Belotero Right; Patients will receive one treatment with Restylane® Silk (left side of the face) and one treatment of Belotero Balance® (right side)	Drug: Restalyne Silk; Drug: Belotero Balance

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Response to therapy as evaluated by investigator using 5-point Merz® Scale	Response to therapy on each side of the lip on day 0 (initial treatment), and subsequent post-treatment days 7, 14, 30, 60, 90, 120, 150, 180, as measured by the blinded evaluator: A 1-point improvement from baseline in superficial, vertical, perioral rhytids based on the 5-point Merz® Scale	Day 0, 7, 14, 30, 60, 90, 120, 150, 180

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response to Therapy- Subject	Response to therapy on each side of the lip on day 0 (initial treatment), and subsequent post-treatment days 7, 14, 30, 60, 90, 120, 150, 180, as measured by the blinded patient: A 20% improvement from baseline in superficial, vertical, perioral rhytids using a linear analog scale	Day 0, 7, 14, 30, 60, 90, 120, 150, 180
Severity grading- Evaluator	Severity grading by a blinded evaluator employing standardized photography in combination with the 5-point Merz® Scale	6 months
VISIA complexion analysis	VISIA complexion analysis (Canfield Imaging Systems, Fairfield, New Jersey) on day 0 (initial treatment), day 30 and when the patient's perioral fine lines have returned to baseline. VISIA analysis will be used to grade the patient's skin by measuring the wrinkles and generating a percentile score.	Day 0, Day 30

Collaborators and Investigators

• Sponsor: The Maas Clinic
• Investigators: Principal Investigator: Corey S. Maas, M.D., The Maas Clinic

Study record dates

Study Major Dates

• Study Start: June 1, 2016
• Primary Completion (ANTICIPATED): January 1, 2017

Study Registration Dates

• First Submitted: June 3, 2016
• First Submitted That Met QC Criteria: June 28, 2016
• First Posted (ESTIMATE): June 29, 2016

Study Record Updates

• Last Update Posted (ESTIMATE): June 29, 2016
• Last Update Submitted That Met QC Criteria: June 28, 2016
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Protective Agents; Adjuvants, Immunologic; Viscosupplements; Hyaluronic Acid
• Other Study ID Numbers: RSB-2015